Methods
allergy
ALLERGY
This prospective randomized double-blinded clinical trial, which adhered to CONSORT guidelines, was approved and was performed from November 2021 to April 2022, in accordance with the Helsinki Declaration of the World Medical Association. The study was reviewed and approved by the Medical Ethics Committee of Xi’an League People’s Hospital, Inner Mongolia Autonomous Region (approval number: YJXM2021YB2, 25/09/2021, Chairman: Hui Jiang) and registered with the China Clinical Trials Registry (registration number: ChiCTR2100052528, 30/10/2021). All patients signed an informed consent form.All patients aged 18–65 years scheduled to undergo elective benign laparoscopic gynecologic surgery at Xing’an Meng People’s Hospital, Inner Mongolia Autonomous Regio were consecutively enrolled. The inclusion criteria were as follows: (1) American Society of Anesthesiologists (ASA) class I or II patient; (2) undergoing benign laparoscopic gynaecological surgery, and (3) consenting voluntarily to participate in the study and signing an informed consent form. The exclusion criteria were as follows: (1) pregnant women; (2) patients categorised in ASA class III and above; (3) emergency surgery; (4) legally protected adults (under judicial protection, guardianship or supervision) deprived of liberty; (5) history of laparotomy, and (6) allergy to experimental drugs.